BIIO.US Bionovate Technologies Corp
- Market cap
- USD 775.00
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2021.
Is BIIO.US undervalued?
Graham numberThe Graham number of Bionovate Technologies Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bionovate Technologies Corp fundamental analysis
No fundamental analysis for Bionovate Technologies Corp yet.
Bionovate Technologies Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bionovate Technologies Corp
Bionovate Technologies Corp., a medical device company, focuses on developing automated treatment for age spots. It intends to develop automated computerized system that treats age spots anywhere on the body. The company targets to sell its systems to physicians and spas worldwide. The company was formerly known as MJP International Ltd. and changed its name to Bionovate Technologies Corp. in December 2017. Bionovate Technologies Corp. was founded in 2010 and is based in Cha…
Full company profileBionovate Technologies Corp financial statements
2021 annualized: Fiscal year 2021 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2021, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bionovate Technologies Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2021 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 28.8K | 8.25K | 4.44K | 6.12K | 5.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.80K | -1.85K | 682.00 | 1.01K | 906.00 | 0.00 | - | - | - | - |
| Operating Income | -87.5K | -91.2K | -48.2K | -38.4K | -87.7K | -119K | -56.5K | -33.1K | -45.4K | -25.1K |
| EBITDA | - | - | - | - | -280K | -1.67M | -56.8K | -33.0K | -45.6K | -25.1K |
| Net Income | -87.5K | -91.2K | -48.2K | -38.4K | -323K | -1.74M | -209K | -122K | -107K | -86.5K |
| EPS | - | - | - | - | -108 | -11 | -1.34 | 0.00 | -0.01 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 66.0K | 967.00 | 617.00 | 936.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 57.4K | 83.9K | 117K | 152K | 229K | 310K | 332K | 397K | 503K | 525K |
| Shareholders' Equity | 8.65K | -82.9K | -116K | -151K | -229K | -310K | -332K | -397K | -503K | -525K |
| Cash & Short-term Investments | 57.7K | 967.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||||||||
| Operating Cash Flow | -64.2K | -56.4K | -311.00 | 429.00 | 10.6K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | - | - | - | 10.6K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Ratios | ||||||||||
| ROE | -1,012.3% | - | - | - | - | - | - | - | - | - |
| ROA | -132.5% | -9,431.7% | -7,812.6% | -4,098.4% | - | - | - | - | - | - |
| Net Profit Margin | -303.5% | -1,105.6% | -1,086.9% | -627.0% | -6,002.8% | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Bionovate Technologies Corp dividends
Bionovate Technologies Corp has not paid dividends in the last 9 fiscal years.
Last stock split: 1:100 on Jan 9, 2020.
Who owns Bionovate Technologies Corp
- Insiders 49.01%
- Institutions 0.00%
- Public & others 50.99%
- Shares outstanding 7.75M
- Free float 3.95M
Bionovate Technologies Corp company profile
- Company name
- Bionovate Technologies Corp
- Ticker
- BIIO.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- June
- Address
- Gewerbestrasse 10, Cham, Switzerland, 6330
- Phone
- 41 646 224 1160
- Website
- bionovate.com
About Bionovate Technologies Corp
Bionovate Technologies Corp., a medical device company, focuses on developing automated treatment for age spots. It intends to develop automated computerized system that treats age spots anywhere on the body. The company targets to sell its systems to physicians and spas worldwide. The company was formerly known as MJP International Ltd. and changed its name to Bionovate Technologies Corp. in December 2017. Bionovate Technologies Corp. was founded in 2010 and is based in Cham, Switzerland. As of October 7, 2020, Bionovate Technologies Corp. operates as a subsidiary of Human Data AG.
Bionovate Technologies Corp management
1- Mr. Timothy JonesPresident, CEO, CFO, Secretary, Treasurer & Director · born 1958